Evaluating two doses of mivacurium for emergency intubation
Evaluation of Effectiveness of Two Different Doses of Mivacurium in Modified Rapid Sequence Intubation for Emergency Surgery ,Prospective Randomized Double Blind Study
This study is testing two different doses of mivacurium to see which one helps people aged 20-60 have a smoother and safer emergency intubation during surgery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 20 Years to 60 Years |
| Sex | All |
| Sponsor | Al-Azhar University Academic / other |
| Locations | 1 site (Cairo, Naser City) |
| Trial ID | NCT06072534 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of two different doses of mivacurium, a non-depolarizing neuromuscular blocking agent, in facilitating rapid sequence intubation during emergency surgeries. The research focuses on monitoring hemodynamic changes and recovery times associated with high doses of mivacurium, aiming to improve intubation conditions and minimize risks such as aspiration. Patients aged 20-60 with ASA classifications 1 and 2 undergoing emergency procedures will be included, while those with certain exclusions will be omitted from the study.
Who should consider this trial
Good fit: Ideal candidates are patients aged 20-60 with ASA classifications 1 and 2 who require emergency surgery.
Not a fit: Patients with allergies, neuromuscular diseases, severe cardiac or pulmonary conditions, or those who refuse participation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the safety and efficiency of emergency intubation procedures.
How similar studies have performed: While the use of mivacurium in emergency settings has been explored, this specific evaluation of dosing and hemodynamic monitoring is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 20-60 year old patients. * American society of anaesthesia (ASA) 1 and 2. * Emergency surgery. Exclusion Criteria: * Refusal. * allergy. * neuromuscular disease. * Suspected desaturation. * Severe cardiac disease. * Severe pulmonary disease.
Where this trial is running
Cairo, Naser City
- Al Azhar University — Cairo, Naser City, Egypt (Recruiting)
Study contacts
- Principal investigator: ismail m ahmed, professor — Al-Azhar University
- Study coordinator: ismail m ahmed, professor
- Email: ismailabdelgawad.623@azhar.edu.eg
- Phone: 00201117310053
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.